Post-discharge mortality in the first wave of COVID-19 in Turkey
Fusun Fakili, Pelin Duru Cetinkaya, Oya Baydar Toprak, S. A. Baris, Nurdan Kokturk, Seval Kul, Burcu Baran Ketencioglu, Pinar Aysert Yildiz, Ilim Irmak, Yonca Sekibag, Sermin Borekci, Bilun Gemicioglu, Emel Azak, Caglar Cuhadaroglu, Gulseren Sagcan, Bugra Kerget, Gulcihan Ozkan, Zeynep Ture, Merve Ercelik, Ozlem Alici, Esra Nurlu Temel, Neslihan Kose Kabil, M Tor, Gulsah Gunluoglu, Sedat Altin, Onder Ozturk, Oya Itil, Hasan Bayram, Oguz Karcioglu, Sait Mulamahmutoglu, Hasan Selcuk Ozger, Tansu Ulukavak Ciftci, Ozlem Ataoglu, P. Y. Gulhan, Ilknur Basyigit, Hasim Boyaci, I. Kivilcim Oguzulgen, Ismail Hanta, Hacer Kuzu Okur, Metin Akgun, A. Fuat Kalyoncu
article (Uluslararası, Hakemli) | Yazar(lar): Fusun Fakili, Pelin Duru Cetinkaya, Oya Baydar Toprak, S. A. Baris, Nurdan Kokturk, Seval Kul, Burcu Baran Ketencioglu, Pinar Aysert Yildiz, Ilim Irmak, Yonca Sekibag, Sermin Borekci, Bilun Gemicioglu, Emel Azak, Caglar Cuhadaroglu, Gulseren Sagcan, Bugra Kerget, Gulcihan O
Objective: To determine post-discharge mortality and associated factors of the first-wave multicenter Turkish Thoracic Society (TTD)-TURCOVID study. Methods: In this retrospective cohort study, we analyzed the data of 18 of 26 centers included in the first TTD-TURCOVID study, and 1 112 cases diagnosed with COVID-19 between 11 March and 31 July 2020 participated in the study. All causes of death after COVID-19 discharge were recorded. Results: The mean age of the patients was (51.07 +/- 16.93) years, with 57.6% male patients. In the cohort group, 89.1% of COVID-19 treatment locations were hospital wards, 3.6% were intensive care units (ICUs), and 7.2% were community outpatients. In the long-term follow-up, the in-hospital mortality rate was 3.6% (95% CI 2.64.8), the post-discharge mortality rate was 2.8% (95% CI 1.9-3.9), and the total mortality was 6.3% (95% CI 5.0-7.8). After discharge, 63.3% of mortality overall occurred during the first six months. Mortality rates in post-discharge follow-ups were 12.7% (95% CI 8.0-30.6) in cancer patients, 10.8% (95% CI 6.3-22.9) in chronic obstructive pulmonary disease patients, 11.1% (95% CI 4.4-22.7) in heart failure patients, 7.8 (95% CI 3.8-14.3) in atherosclerotic heart disease patients, and 2.3% (95% CI 0.8-5.6) in diabetes mellitus patients. In smokers/ex-smokers, the all-mortality rates were higher than in non-smokers. Conclusions: This multicenter study showed that patients over 65 years of age, males, former/active smoker, ICU stay, lung, heart disease, and malignancy should be followed up for at least the first six months after discharge due to COVID-19.